The Mucopolysaccharidosis Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Mucopolysaccharidosis Treatment Market:
https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report
According to The Business Research Company’s Mucopolysaccharidosis Treatment Global Market Report 2024, The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.2 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to enzyme replacement therapy (ert), improved diagnostic tools, advocacy and awareness, gene therapy development, healthcare infrastructure development.
The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancements in gene editing, regulatory changes and support, patient access initiatives, emerging therapeutic modalities, precision medicine approaches. Major trends in the forecast period include caregiver support programs, focus on symptom management, education and training initiatives, expanded global access, advances in biomarker development.
The increasing prevalence of various forms of mucopolysaccharidosis is expected to propel the growth of the mucopolysaccharidosis treatment market going forward. Mucopolysaccharide is a form of complex carbohydrate that accumulates in bodily tissues because the individual affected lacks the particular enzyme required to digest it. Mucopolysaccharidosis (MPS) therapy can help prevent disease development by lowering glycosaminoglycan (GAG) formation in the body, controlling symptoms, and preventing complications through various therapeutic approaches. For instance, in February 2021, according to a report shared by National Library of Medicine, a US-based medical library, there were 3.62 MPS I and MPS VI births for every 100,000 live births. MPS III represented 11% of all cases, with a calculated rate of 1.8 per 100,000 live births. Therefore, the increasing prevalence of various forms of mucopolysaccharidosis will drive the mucopolysaccharidosis treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=11942&type=smp
The mucopolysaccharidosis treatment market covered in this report is segmented –
1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy
2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases
3) By Route of Administration: Intravenous, Intracerebroventricular
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Product innovation is a key trend gaining popularity in the mucopolysaccharidosis treatment market. Major companies operating in the mucopolysaccharidosis treatment market are focused on new product innovations to sustain their position in the market. For instance, in March 2021, JCR Pharmaceuticals, a Japan-based pharmaceuticals company, announced the approval of IZCARGO (Pabinafusp Alfa) for the treatment of mucopolysaccharidosis II (MPS II, or Hunter syndrome) in Japan. It is the first approved enzyme replacement therapy for MPS II to penetrate the blood-brain barrier via intravenous administration, validating JCR’s J-Brain Cargo Technology. The product is a recombinant iduronate-2-sulfatase enzyme replacement therapy (ERT) that uses J-Brain Cargo, a proprietary technology that delivers therapeutics across the blood-brain barrier (BBB). It is the first-ever approved ERT that crosses the BBB via intravenous administration, which could be life-changing for people with lysosomal storage disorders (LSDs) like MPS II.
The mucopolysaccharidosis treatment market report table of contents includes:
1. Executive Summary
2. Mucopolysaccharidosis Treatment Market Characteristics
3. Mucopolysaccharidosis Treatment Market Trends And Strategies
4. Mucopolysaccharidosis Treatment Market – Macro Economic Scenario
…
32. Global Mucopolysaccharidosis Treatment Market Competitive Benchmarking
33. Global Mucopolysaccharidosis Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Mucopolysaccharidosis Treatment Market
35. Mucopolysaccharidosis Treatment Market Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
